ArticleFrontiers in medicine2025
Global burden of childhood Burkitt lymphoma (1990-2021): epidemiological trends, regional disparities, and projections for 2035 from the Global Burden of Disease Study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Observational
- Trends and future projections of Hodgkin and Non-Hodgkin lymphoma burden in Chinese children and adolescents (1990-2043): insights from the GBD 2023 database.Annals of hematology · 2026Article
- Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Burkitt lymphoma (BL) is a highly aggressive pediatric B-cell lymphoma with marked geographic heterogeneity. Up-to-date global estimates are needed to inform prevention and care. Methods: We analyzed Global Burden of Disease (GBD) 2021 data to estimate incidence, mortality, and disability-adjusted life years (DALYs) for childhood BL (0-14 years) from 1990 to 2021 across 204 countries/territories, stratified by sex, age, region, and Sociodemographic Index (SDI). Trends were summarized using joinpoint annual percent change and estimated annual percentage change (EAPC). Bayesian age-period-cohort models projected the burden to 2035. Findings: In 2021, there were 4,083 incident BL cases globally [95% uncertainty interval (UI) 2,688-5,171]. The global incidence rate was 0.20 per 100,000 (95% UI 0.13-0.26) versus 0.16 per 100,000 (95% UI 0.10-0.23) in 1990. Burden varied substantially by development level: the low-SDI region had the highest incidence rate (0.44 per 100,000, 95% UI 0.26-0.59), mortality rate (0.43 per 100,000, 95% UI 0.25-0.58), and DALY rate (36.19 per 100,000, 95% UI 21.00-48.64). High-SDI regions showed lower mortality rates and evidence of declines, consistent with broader access to timely diagnosis, multi-agent chemotherapy, and supportive care. By 2035, the incidence rate is expected to reach 0.15 (95% CI 0.11-0.19) per 100,000, the mortality rate to 0.10 (95% CI 0.07-0.13) per 100,000, and the DALY rate to 8.21 (95% CI 5.98-10.43) per 100,000. Interpretation: Global BL rates appear broadly stable, with pronounced inequities concentrated in low-SDI settings. Apparent improvements are heterogeneous, not universal, and are most evident in high-SDI regions where treatment and supportive care are widely available. Projections to 2035 suggest modest declines in global rates, contingent on sustained malaria control and expanded access to diagnosis and curative therapy in high-burden regions. Targeted investments linking infection control with pediatric oncology capacity are required to reduce the global burden of childhood BL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.